{"id":"https://openalex.org/W4390613401","doi":"https://doi.org/10.1158/1078-0432.c.7010473","title":"Data from A Phase II Trial of the CD40 Agonist Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Disease Progression on Anti-PD-1","display_name":"Data from A Phase II Trial of the CD40 Agonist Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Disease Progression on Anti-PD-1","publication_year":2024,"publication_date":"2024-01-05","ids":{"openalex":"https://openalex.org/W4390613401","doi":"https://doi.org/10.1158/1078-0432.c.7010473"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.c.7010473","doi":"https://doi.org/10.1158/1078-0432.c.7010473","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.7010473","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1078-0432.c.7010473","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5066292518","display_name":"Sarah Ann Weiss","orcid":"https://orcid.org/0000-0002-1106-7089","observed_orcids":["https://orcid.org/0000-0002-1106-7089"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sarah A. Weiss","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-1106-7089","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102750517","display_name":"Mario Sznol","orcid":"https://orcid.org/0000-0003-4137-9662","observed_orcids":["https://orcid.org/0000-0003-4137-9662"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mario Sznol","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-4137-9662","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084480627","display_name":"Montaser F. Shaheen","orcid":"https://orcid.org/0009-0006-1542-2267","observed_orcids":["https://orcid.org/0009-0006-1542-2267"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Montaser Shaheen","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0006-1542-2267","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071710676","display_name":"Miguel\u2010\u00c1ngel Berciano\u2010Guerrero","orcid":"https://orcid.org/0000-0002-5437-5196","observed_orcids":["https://orcid.org/0000-0002-5437-5196"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Miguel-Angel Berciano-Guerrero","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-5437-5196","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058294413","display_name":"Eva Mu\u00f1oz\u2010Couselo","orcid":"https://orcid.org/0000-0001-7556-7608","observed_orcids":["https://orcid.org/0000-0001-7556-7608"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Eva Mu\u00f1oz-Couselo","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-7556-7608","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055964030","display_name":"Delvys Rodr\u00edguez\u2010Abreu","orcid":"https://orcid.org/0000-0003-0506-1366","observed_orcids":["https://orcid.org/0000-0003-0506-1366"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Delvys Rodr\u00edguez-Abreu","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-0506-1366","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020352800","display_name":"Valentina Boni","orcid":"https://orcid.org/0000-0002-8675-0018","observed_orcids":["https://orcid.org/0000-0002-8675-0018"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Valentina Boni","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-8675-0018","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012671311","display_name":"Lynn Mara Schuchter","orcid":"https://orcid.org/0000-0002-0523-4346","observed_orcids":["https://orcid.org/0000-0002-0523-4346"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lynn M. Schuchter","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-0523-4346","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072143967","display_name":"Mar\u00eda Gonz\u00e1lez\u2010Cao","orcid":"https://orcid.org/0000-0003-3791-540X","observed_orcids":["https://orcid.org/0000-0003-3791-540X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Maria Gonzalez Cao","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-3791-540X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009056091","display_name":"Ana Maria Arance","orcid":"https://orcid.org/0000-0003-2896-1957","observed_orcids":["https://orcid.org/0000-0003-2896-1957"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ana Arance Fernandez","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-2896-1957","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073006325","display_name":"Wei Wei","orcid":"https://orcid.org/0000-0003-1263-5620","observed_orcids":["https://orcid.org/0000-0003-1263-5620"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Wei Wei","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-1263-5620","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024497224","display_name":"Apar Kishor Ganti","orcid":"https://orcid.org/0000-0003-3724-2671","observed_orcids":["https://orcid.org/0000-0003-3724-2671"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Apar Kishor Ganti","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-3724-2671","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035148529","display_name":"Ralph J. Hauke","orcid":"https://orcid.org/0000-0002-0243-7279","observed_orcids":["https://orcid.org/0000-0002-0243-7279"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ralph J. Hauke","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-0243-7279","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068271097","display_name":"Alfonso Berrocal","orcid":"https://orcid.org/0009-0001-7457-7879","observed_orcids":["https://orcid.org/0009-0001-7457-7879"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alfonso Berrocal","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0001-7457-7879","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072917229","display_name":"Nicholas O. Iannotti","orcid":"https://orcid.org/0009-0004-1379-9082","observed_orcids":["https://orcid.org/0009-0004-1379-9082"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nicholas O. Iannotti","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0004-1379-9082","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049247537","display_name":"Frank James Hsu","orcid":"https://orcid.org/0009-0005-4156-2995","observed_orcids":["https://orcid.org/0009-0005-4156-2995"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Frank J. Hsu","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0005-4156-2995","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5001175430","display_name":"Harriet M. Kluger","orcid":"https://orcid.org/0000-0002-4932-9873","observed_orcids":["https://orcid.org/0000-0002-4932-9873"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Harriet M. Kluger","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-4932-9873","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.00139999995008111,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cd40-agonist","display_name":"CD40 agonist","score":0.8510000109672546},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.9980000257492065},{"id":"https://openalex.org/keywords/metastatic-melanoma","display_name":"metastatic melanoma","score":0.925000011920929},{"id":"https://openalex.org/keywords/anti-pd-1-resistance","display_name":"anti-PD-1 resistance","score":0.9700000286102295},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.7440000176429749},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.8949999809265137},{"id":"https://openalex.org/keywords/durable-response","display_name":"durable response","score":0.7020000219345093},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.8240000009536743},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.42899999022483826}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8379600048065186},{"id":"https://openalex.org/C2778594517","wikidata":"https://www.wikidata.org/wiki/Q2260058","display_name":"Chills","level":2,"score":0.6699724197387695},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6355763673782349},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.617730438709259},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.6018344163894653},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5789452791213989},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5752573609352112},{"id":"https://openalex.org/C2778616394","wikidata":"https://www.wikidata.org/wiki/Q474959","display_name":"myalgia","level":2,"score":0.5743656158447266},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.5575747489929199},{"id":"https://openalex.org/C2780852908","wikidata":"https://www.wikidata.org/wiki/Q127076","display_name":"Vomiting","level":2,"score":0.4690100848674774},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.4676283001899719},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.4663865566253662},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.2613436281681061},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2492748200893402},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.19853147864341736}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1078-0432.c.7010473","doi":"https://doi.org/10.1158/1078-0432.c.7010473","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.7010473","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.c.7010473","doi":"https://doi.org/10.1158/1078-0432.c.7010473","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.7010473","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4390608839","https://openalex.org/W4385514977","https://openalex.org/W3211448706","https://openalex.org/W4390612430","https://openalex.org/W4402784101","https://openalex.org/W4308396206","https://openalex.org/W4282917700","https://openalex.org/W7154696086","https://openalex.org/W7204869354","https://openalex.org/W7155084010"],"abstract_inverted_index":{"Abstract":[0],"Purpose:":[1],"Disease":[2],"progression":[3,78],"during":[4],"or":[5,205],"after":[6],"anti-PD-1-based":[7],"treatment":[8],"is":[9,15],"common":[10,180],"in":[11,70,232,237,248],"advanced":[12,73],"melanoma.":[13],"Sotigalimab":[14,213],"a":[16,53,171,217,238],"CD40":[17,40],"agonist":[18],"antibody":[19],"with":[20,43,72,222,242],"unique":[21],"epitope":[22],"specificity":[23],"and":[24,66,97,124,136,168,197,234],"Fc-receptor":[25],"binding":[26],"profile":[27,220],"optimized":[28],"for":[29,99,104,113,154],"activation":[30],"of":[31,63,116,141,207,226,240],"CD40-expressing":[32],"antigen":[33],"presenting":[34],"cells.":[35],"Preclinical":[36],"data":[37],"indicated":[38],"that":[39],"agonists":[41],"combined":[42],"anti-PD1":[44],"could":[45],"overcome":[46],"resistance":[47],"to":[48,59,85,176,210],"anti-PD-1.":[49,80],"Methods:":[50],"We":[51],"conducted":[52],"multi-center,":[54],"open-label,":[55],"phase":[56],"II":[57],"trial":[58],"evaluate":[60],"the":[61,87,128,223],"combination":[62,230],"sotigalimab":[64,208],"0.3mg/kg":[65],"nivolumab":[67,215],"360mg":[68],"q3wk":[69],"patients":[71,150,159,241],"melanoma":[74],"following":[75],"confirmed":[76,107],"disease":[77,153],"on":[79],"The":[81,178,229],"primary":[82],"objective":[83,88],"was":[84,143],"determine":[86],"response":[89,142],"rate":[90],"(ORR).":[91],"Results:":[92],"Thirty-eight":[93],"subjects":[94],"were":[95,102,111,182,200],"enrolled":[96],"evaluable":[98,103],"safety.":[100],"Thirty-three":[101],"activity.":[105],"Five":[106],"partial":[108],"responses":[109,236],"(PR)":[110],"observed":[112],"an":[114],"ORR":[115],"15%.":[117],"Two":[118,148],"PRs":[119],"are":[120],"ongoing":[121],"at":[122,133,144,162],"45.9+":[123],"26+":[125],"months":[126],"while":[127],"other":[129],"3":[130,173],"responders":[131],"relapsed":[132],"41.1,":[134],"18.7,":[135],"18.4":[137],"months.":[138,147,157],"Median":[139],"duration":[140],"least":[145,163],"26":[146],"additional":[149],"had":[151,216],"stable":[152],">":[155],"6":[156],"Thirty-four":[158],"(89%)":[160],"experienced":[161,170],"one":[164],"adverse":[165],"event":[166],"(AE)":[167],"13%":[169],"grade":[172],"AE":[174],"related":[175],"sotigalimab.":[177],"most":[179],"AEs":[181],"pyrexia,":[183],"chills,":[184],"nausea,":[185],"fatigue,":[186],"pruritus,":[187],"elevated":[188],"liver":[189],"function,":[190],"rash,":[191],"vomiting,":[192],"headache,":[193],"arthralgia,":[194],"asthenia,":[195],"myalgia,":[196],"diarrhea.":[198],"There":[199],"no":[201],"treatment-related":[202],"SAEs,":[203],"deaths,":[204],"discontinuation":[206],"due":[209],"AEs.":[211],"Conclusions:":[212],"plus":[214],"favorable":[218],"safety":[219],"consistent":[221],"toxicity":[224],"profiles":[225],"each":[227],"agent.":[228],"resulted":[231],"durable":[233],"prolonged":[235],"subset":[239],"anti-PD-1-resistant":[243],"melanoma,":[244],"warranting":[245],"further":[246],"evaluation":[247],"this":[249],"setting.":[250]},"counts_by_year":[],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2024-01-07T00:00:00"}